When: $570-572 retest with 50 SMA hold on close + MACD histogram turning positive

Then: Add 2-3% on confirmation

When: Reclaim 10 EMA ($610) on volume ≥2M with MACD histogram positive

Then: Add back trimmed portion

When: $647+ on volume ≥3M with MACD positive

Then: Reassess to Overweight

HOLD full position with hard stop at $576.56. If $576.56 fails on a closing basis, reevaluate and trim on the retest with better information. If it holds, ride the consolidation into Q3 earnings catalyst. Do not trim into a momentum oscillator cross or reduce exposure without a named alternative.

• Consolidation range is $600 to $618; trim at $610 is selling at the bottom, giving up $8-$10 of fill quality on a 25-30% position
• 5.6% buffer is a stop, not protection; ATR is $15.56 implying ~$30 daily range where gap-down exit could be $558-$565 vs stated $576
• MACD value of 8.58 vs signal 13.47 with RSI at 51.48 (neutral) and stock above 50 SMA and 200 SMA indicates healthy consolidation, not regime change; MACD bearish crosses in uptrends have ~50% historical false-positive rate
• 2.69 million shares on September 8th was single-session, single-data-point distribution print without follow-through; no 3-4 consecutive down days with rising volume
• No alternative named for redeployment; selling high-quality defensive compounder in healthcare sector outperforming S&P by 11.5 percentage points creates performance erosion
• Transaction costs, potential short-term capital gains, and tax liability crystallization are ignored costs of trim
• Leverage is manageable: Q2 operating cash flow $2.13B covers interest expense 5x over; net debt to FCF is 6.2x for BBB+ rated platform
• 10.5% revenue growth delivered; UBS projects mid-single-digit organic growth for 2027
• Hard stop at $576.56 below 50 SMA is the actual medium-term trend break level, not the 5.6% buffer level

→ vs aggressive: Trim math is wrong: selling at $610 into a $600-$618 consolidation range instead of resistance at $618-$620; $8-$10 per share given up on 25-30% position

→ vs aggressive: 5.6% buffer is a stop, not downside protection; ATR of $15.56 means a single day range of $30+ where gap-down exit would be $558-$565, not $576

→ vs aggressive: MACD bearish cross with value 8.58 vs signal 13.47 is a statistically unreliable false signal in an uptrend; RSI neutral at 51.48 and stock above both SMAs confirms intact uptrend, not breakdown

→ vs aggressive: September 8th volume of 2.69 million shares is one session of distribution without follow-through; extrapolating single data point into structural flow reversal is pattern-matching noise, not risk intelligence

→ vs aggressive: 25-30% redeployment into 'better risk-reward setups' has zero named alternatives; selling defensively levered compounder into underperforming sector creates cash drag with no replacement thesis

→ vs neutral: Agrees neutral analyst got the setup right: defensive compounder with rising forward EPS, intact medium/long-term trend, and well-serviced leverage at 6.2x net debt/FCF for BBB+ platform

HOLD with 10-15% tactical trim at resistance; hard stop at $576.56; re-engagement rule to add back trimmed portion upon reclaiming 10 EMA with volume and MACD confirmation

• MACD bearish cross (8.58 vs signal 13.47) is momentum decay within still-intact medium-term uptrend; RSI at 51.48 is neutral
• Three convergent short-term signals inside a six-week catalyst gap with risk-off macro backdrop elevate joint probability of meaningful pullback versus any single signal
• Conservative analyst's 50 SMA support at $576.56 is the appropriate hard stop line on a closing basis
• ATR of $15.56 means single normal trading day spans $30 in range; gap-down scenarios could execute stop below $576.56
• Proper sell-into-resistance execution zone is $612-$618, not the $610 bottom of the range
• Re-engagement rule: reclaim 10 EMA at $609.94 on above-average volume with positive MACD histogram triggers adding back 10-15%
• Q3 earnings in approximately six weeks is a real catalyst with directional risk in both directions
• Interest expense headwind of 6-7% on EPS in a 93% no-cut environment is a real structural pressure, not catastrophic but not dismissible
• Aggressive analyst's $23 downside protection math assumes clean non-gapping execution to $576, which ATR data contradicts
• Conservative analyst's refusal to take any partial action leaves 5.6% drawdown exposure unmitigated if 50 SMA breaks

→ vs aggressive: MACD bearish cross inside intact uptrend carries ~50% false-positive rate historically; calling consolidation pattern a breakdown is most common analytical mistake in technical analysis

→ vs aggressive: 2.69 million share print on September 8th is single-session data point with no follow-through; genuine institutional distribution requires 3-5 consecutive sessions of rising volume on declining price

→ vs aggressive: ATR of $15.56 means stops execute below $576.56 in gap-down scenarios; cannot use gap risk to justify inaction in one paragraph while ignoring it to justify trim in another

→ vs aggressive: Recommending 25-30% trim with no named alternative setups; selling high-quality defensive compounder (beta 0.85, healthcare up 23%) into cash drag is not risk management

→ vs conservative: MACD has decayed 61% from peak in two weeks with widening histogram; dismissing three converging signals as noise fails confirmation discipline

→ vs conservative: Correctly identifies $600-$618 consolidation range but then recommends hard stop with no trim, leaving 5.6% drawdown unmitigated; 'doing less, more carefully' is just doing less

→ vs conservative: Interest expense headwind ($7.2B new debt) directly compresses EPS trajectory in 93% no-cut environment; dollar coverage does not equal earnings trajectory neutrality

→ vs conservative: Missing re-engagement rule; no defined path to re-enter if stopped out rather than permanent reduction